Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-Small Cell Lung Cancer Metastatic × tepotinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Lung Neoplasms 2 Non-Small Cell Lung Cancer Metastatic 1 Neoplasms 1 Gastrointestinal Neoplasms 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Pemetrexed 2 Nivolumab 2 Cisplatin 2 Carboplatin 2 tepotinib 1 pembrolizumab 1 patritumab deruxtecan 1 lazertinib 1 durvalumab 1 atezolizumab 1 Taxes 1 Radiotherapy 1 Radiosurgery 1 Ipilimumab 1 BO-112 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Samsung Medical Center

Phase 2 Recruiting

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡